secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019449
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q1 net loss $31.6M; BLA resubmission expected H2 2024; closed $75M offering
--------------------------------------------------------------------------------

- Net loss $31.6M ($1.16/share) vs. $9.1M loss a year ago; cash $62.7M at March 31, up from $52.6M.
- Closed $75M underwritten offering on May 7, 2024; cash runway extended into 2026.
- FDA CRL in April 2024 cited CMC deficiencies; no efficacy/safety issues; BLA resubmission planned H2 2024.
- R&D expense $7.2M (down 10% YoY); G&A expense $7.1M (up 78% YoY).
- Entered $50M credit facility in Jan 2024, drew $20M first tranche.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/0001493152-24-019449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer